Tag: Research

9/8/20--Rigorous empirical studies of the effect of a policy intervention seek to consider (or estimate) what outcomes are (or would be) with the policy compared with what outcomes are (or would be) without the policy. Read

8/27/20--A new analysis of cannabis research funding in the United States, Canada, and the United Kingdom has found that $1.56 billion was directed to the topic between 2000 and 2018—with about half of the money spent on understanding the potential harms of the recreational drug. Read

8/29/20--A few start-ups and niche firms are developing small molecules that are inspired by CBD and other natural products from cannabis plants as potential drugs for a wide array of diseases. Human clinical trials are underway or just wrapping up for some of these drug candidates, while others are still in research or preclinical stages. Read

7/29/20--Until very recently, no companies would manufacture medical-grade psychedelics, which made getting regulatory approval for clinical research—especially clinical trials—very difficult and in some countries (eg, Germany) impossible. Read

9/1/20--The evidence found in this study indicates that CBD is a promising adjunct therapy for the treatment of cocaine dependence due to its effect on: cocaine reward effects, cocaine consumption, behavioral responses, anxiety, neuronal proliferation, hepatic protection and safety. Moreover, clinical trials are strongly required to determine whether the findings in animal models occur in humans diagnosed for cocaine or crack cocaine use disorder. Read

6/20/20--Studies of individual pure compounds found in cannabis have demonstrated, as highlighted in this review article, that many of the compounds present in cannabis could be part of a therapeutic solution for specific problems found during cancer treatment. However, additional clinical studies are needed to clarify whether some of these compounds (alone or in combination with other anticancer agents) could be useful in anticancer therapies. Read

6/3/20--Shares in Philadelphia-based cannabis company FSD Pharma spiked 324% in premarket trading this morning on news that it had been granted approval by the Food and Drug Administration to submit an application for a clinical trial using a synthetic drug that mimics the action of a molecule found in marijuana to treat COVID-19. Read

6/1/20--U.S. researchers lack appropriate access to commercially available cannabis products for clinical trials. Meanwhile, patients continue to use state-sanctioned products marketed as medicines in the absence of evidence to support their benefits or define their harms. Read

5/27/20--Ethos Cannabis and the Sidney Kimmel Medical College at Thomas Jefferson University have launched their first studies under Pennsylvania’s medical cannabis research program. Pennsylvania’s 2016 medical cannabis law allows medical cannabis operators to seek “clinical registrant” licenses to partner with one of the state’s medical schools, called “academic clinical research centers,” to orchestrate patient-facing clinical studies into the benefits of medical cannabis. Read

5/1/20--Sue Sisley of the Scottsdale Research Institute (SRI), who is involved in a case that forced the release of a previously “secret” Justice Department document about federally authorized marijuana research this week, is now calling on Congress to urge administrative action to more rapidly expand studies into the therapeutic potential of cannabis. Read

4/1/20--According to an article published in The New York Times, wherever marijuana is legal, companies are claiming that they have figured out how to produce a bespoke high. Some of the research these companies cite to support what they are advertising has been published and peer-reviewed, but much of the recent work on the effects of cannabis has been conducted privately, and the companies are guarding their results as trade secrets. Read

4/4/20--Researchers from the University of Miami are studying the effects of the coronavirus on medical marijuana users and document how these individuals are faring during the pandemic. The study will also look at whether sharing joints and vapes could be a contributing factor to the spread of the coronavirus. Read

3/23/20--The Drug Enforcement Administration is proposing to amend its regulations to comply with the requirements of the Controlled Substances Act, including consistency with treaty obligations, in order to facilitate the cultivation of marihuana for research purposes and other licit purposes. Read

2/3/20--Today, White House Office of National Drug Control Policy (ONDCP) Director Jim Carroll released the Trump Administration’s National Drug Control Strategy, which establishes the President’s priorities for addressing the challenge of drug trafficking and use. Read

1/19/20--A compound made by cannabis plants has been found to wipe out drug-resistant bacteria, raising hopes of a new weapon in the fight against superbugs. Scientists screened five cannabis compounds for their antibiotic properties and found that one, cannabigerol (CBG), was particularly potent at killing methicillin-resistant Staphylococcus aureus (MRSA), one of the most common hospital superbugs. Read

1/10/20--Two newfound cannabinoids have been discovered in the glands of the Cannabis plant, and one of them may be at least 30 times as potent as the high-inducing compound THC. However, it's still unknown if it causes a high or has medical benefits. Read

11/11/19--Washington State University has made a deal with a California-based company in hopes of attaining pharmacy-grade marijuana for future study. The school’s Collaborative for Cannabis Policy, Research and Outreach announced the partnership with Biopharmaceutical Research Co. in a news release last week. Read

11/7/19--Results from a study published in the British Journal of Clinical Pharmacology may help explain why cannabidiol -- a chemical component of marijuana with no psychoactive properties -- reduces the frequency of seizures in patients with a severe form of epilepsy. The effect may be explained by a drug-drug interaction between cannabidiol and the anti-seizure medication clobazam. Read

9/30/19--The annotated genome allows, for the first time, the use of classical genetics and proteomics tools for the interrogation of these plants. Furthermore, the presence of an annotated genome within the NCBI Genome browser now permits any researcher with a web browser to manually examine or BLAST genetic sequences, vastly reducing the resources required to create primers to amplify genes from the plants or microbial contaminants that may affect them. Read

8/12/19--A University of Minnesota study examined whether eating high-fat foods after taking CBD increased the body’s absorption of CBD. The study tested whether fasting or a high fat meal has an effect when cannabidiol oral capsules were taken by patients. The study found CBD exposure is vastly increased when CBD is taken with high fatty foods; when compared to fasting, taking CBD with food increased the amount of CBD in the body by four-times and the maximum amount recorded in the participants’ blood by 14-times. Read

5/10/19--Researchers at the University of Washington School of Medicine are recruiting pregnant women to participate in their "Moms + Marijuana" study. The study will analyze whether prenatal marijuana use -- primarily to control nausea, and in the absence of alcohol, tobacco and any illicit drugs -- affects their child's brain development and cognitive, motor and social skills. Read

4/30/19--The goal of this study was to investigate Cannabidiol (CBD) hepatotoxicity in 8-week-old male B6C3F₁ mice. CBD exhibited clear signs of hepatotoxicity, possibly of a cholestatic nature. The involvement of numerous pathways associated with lipid and xenobiotic metabolism raises serious concerns about potential drug interactions as well as the safety of CBD. Read

3/18/19--The cannabis-derived product, CBD, is appearing in jelly beans — designed by David Klein, the man who created Jelly Belly candies. Klein told the website that he doesn’t want to make any unfounded health claims about his new product but is sure that it “will help the world.” Read

12/3/18--The National Institutes of Health announced today that enrollment for the Adolescent Brain Cognitive Development (ABCD) Study is now complete and, in early 2019, scientists will have access to baseline data from all ABCD Study participants. Read

3/3/19--Denver's only cannabis research center is proceeding with developing a seed-to-sale marijuana-tracking system that no one in the industry says they want. That tracking system was the mandate of a bill introduced into the Legislature during last year's session that lawmakers rejected twice, primarily because the state's marijuana industry loudly told them they don't want to add a foreign substance to their product. Read

12/13/18--Oral spray containing two compounds derived from the cannabis plant reduced spasticity compared with placebo in patients already taking anti-spasticity drugs. Read

11/19/18--The Washington Liquor and Cannabis Board says it has issued the state's first license to grow marijuana for research. Verda Bio Research in Seattle says it will be growing marijuana to conduct basic research on some of the plant's lesser-known compounds. Read

11/7/18--The National Center for Complementary and Integrative Health (NCCIH) intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for research on minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Read

9/12/18--The findings of a new study, published in the International Journal of Drug Policy, demonstrate a high level of understanding among people who use drugs regarding ways to prevent an overdose and some adoption of these methods, but the researchers assert that more needs to be done to prevent overdoses. Read

9/11/18--In an editorial published in Spectrum, Shaun Hussain, director of the Infantile Spasms Program at the University of California, Los Angeles Mattel Children’s Hospital, addresses the cumbersome regulations discouraging many talented and motivated researchers from investigating the potential value of marijuana. Hussain openly expresses his views about marijuana containing 100 mostly unexplored chemicals (known collectively as cannabinoids), any one of which could aid the treatment of not just epilepsy and autism but any number of conditions. Read

9/9/18--British scientists have found how a substance in the marijuana plant acts in the brain to reduce abnormal activity in patients at risk of psychosis. Their findings suggest that the substance could be used in a possible treatment for the condition. Read

9/3/18--Dr. Jeffrey Chen, director of the Cannabis Research Initiative at the University of California, Los Angeles, is spearheading a cannabis initiative team at UCLA to conduct a high-quality clinical study of the painkilling properties of pot — and perhaps stem the opioid epidemic. Dr. Chen says this initiative will be one of the first, randomized, double-blind, placebo-controlled studies in the world dedicated to the study of cannabis and pain. Before the study can begin, however, the researchers need approval from the Food and Drug Administration and the Drug Enforcement Administration, along with funding. Read

8/9/18--The first controlled study examining marijuana as a treatment for post-traumatic stress disorder needs just a handful more U.S. military veterans to volunteer as test subjects before it can be completed, the study's nonprofit sponsor announced Thursday. Read

3/8/18--A police investigation targeting Brazil’s most prominent marijuana researcher Elisaldo Carlini, a retired professor of psychopharmacology at the Federal University of São Paulo (Unifesp), has ignited a wave of protest among scientists. They say that the move by authorities from the state of São Paulo threatens research freedoms at a time when science in the country faces severe problems because of draconian budget cuts. On March 1, researchers, students, and staff at Unifesp gathered on campus to express their support for Carlini and to protest against what they perceived to be an attack on the university. Read

12/28/17--GW Pharmaceuticals (NASDAQ:GWPH) announces that the FDA has accepted for filing with Priority Review its recently submitted New Drug Application (NDA) for Epidiolex (cannabidiol or CBD), an investigational treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, two rare and difficult to treat conditions of childhood-onset epilepsy. The Prescription Drug User Fee Act goal date for completion of the FDA review of the Epidiolex NDA is June 27, 2018. Read

12/12/17--A chemical found in marijuana, known as tetrahydrocannabinol, or THC, has been found to potentially slow the process in which mental decline can occur in up to 50 percent of HIV patients, says a new Michigan State University study. Read

12/10/17--According to Melvin Livingston, lead author of a recent study and an assistant professor at UNT Health Science Center, marijuana use may reduce opioid-related deaths. The study, published in October, indicated legal recreational marijuana use reduced opioid overdose deaths in Colorado by 6 percent during a two-year-period beginning in 2013. But researchers only had two years of data on legal recreational marijuana use to draw from. Read

12/8/17--Raphael Mechoulam started his first marijuana project by walking into a police station and asking for some confiscated weed—for research purposes. Decades later, the 87-year-old Israeli chemist is known widely as the “father of marijuana research,” after he used those 5 kilos to discover THC (marijuana’s psychoactive ingredient) in the 1960s, and then later discovered the structure of CBD. Read

12/1/17--Alcoholic beverage sales fell by 15 percent following the introduction of medical marijuana laws in a number of states, according to a new working paper by researchers at the University of Connecticut and Georgia State University. The study adds to a growing body of evidence showing that marijuana availability can reduce alcohol consumption. Read

11/29/17--Frequent cannabis users enrolled in a Medication-Assisted Treatment for opioid addiction exhibit greater associations between pain and negative affects (anxiety and depression) compared with less-frequent users, according to findings from a study published in Addictive Behaviors. Because this cross-sectional study relied on self-reported data for cannabis use frequency, the investigators note it does not establish a causal relationship between the frequency of cannabis use and the association between pain and negative affect. Read

11/28/17--A synthetic cannabis-like drug in a pill was safe and effective in treating obstructive sleep apnea in the first large multi-site study of a drug for apnea funded by the National Institutes of Health. The study was conducted at Northwestern Medicine and the University of Illinois at Chicago (UIC). Read

11/27/17--University of New Mexico researchers say the legal availability of medical marijuana has the potential to reduce opioid use among chronic pain patients. The results indicate a strong correlation between enrollment in New Mexico’s medical marijuana program and cessation or reduction of opioid use. Read

11/6/17--GW Pharma's drug Epidiolex, a treatment that, in the company's words, "is a pharmaceutical formulation of purified cannabidiol (CBD), which is in development for the treatment of several rare childhood-onset epilepsy disorders," has completed its FDA New Drug Application to be marketed in the U.S. Additionally, it has been granted the FDA's rare pediatric-disease and orphan-drug designations, plus the potentially very helpful Fast Track designation. Read

11/2/17--The CannaVan is a cutting-edge, marijuana research vehicle being used by researchers to drive around federal drug laws, while studying participants who are regular marijuana users. The interdisciplinary lab studies brain science, health, and addiction. In short, when the van shows up, the participants enter sober and run through a battery of tests. Then they go back into their homes, get as high as they want, and return to the van for the same tests. Read

10/26/17--University of Florida Health doctors have begun a new study looking at the health effects of marijuana on people with HIV, including its potential as an alternative to addictive opioids. According to Dr. Robert Cook, the study’s lead investigator, the doctors will be monitoring the patients and their marijuana use. They will be exploring both negative and positive effects of using cannabis as medicine. Read

10/25/17--A pre-clinical study led by Indiana University scientists reports a promising step forward in the search for pain relief methods without the addictive side effects behind the country's current opioid addiction crisis. The research, which appears in the journal Biological Psychiatry, finds that the use of compounds called positive allosteric modulators, or PAMs, enhances the effect of pain-relief chemicals naturally produced by the body in response to stress or injury. Read

10/16/17--Marijuana legalization in Colorado led to a “reversal” of opiate overdose deaths in that state with opioid-related deaths decreasing more than 6% in the following 2 years, according to new research published in the American Journal of Public Health. Authors Melvin D. Livingston, Tracey E. Barnett, Chris Delcher, and Alexander C. Wagenaar stress that their results are preliminary, given that their study encompasses only two years of data after the state’s first recreational marijuana shops opened in 2014. Read

10/16/17--Officials in Colorado are skeptical about a new study that found nearly one fewer person per month died of an opioid overdose in Colorado after the start of legal cannabis sales in 2014 compared to before. The Denver Post reports that the paper’s authors stop short of saying that legalization caused the reversal, instead saying that legalization was “associated” with a decline in opioid deaths. The authors also caution that the study looks only at a small sliver in time because legalization is still relatively new. Read

9/16/17--Utah’s Sen. Orrin Hatch favors medical marijuana research, and he believes the administrative barriers need to be removed preventing legitimate research into medical marijuana, which is why he decided to roll out the Marijuana Effective Drug Study Act. Some complain that the bill Hatch favors is too little, too late. That, by emphasizing the need for research and regulatory rearrangment, the measure is not bold enough and could actually slow down progress toward allowing people in deep and immediate need to take advantage of the plant’s curative and palliative powers now. Read

9/15/17--In laboratory studies using mice, researchers have been able to switch off the impulse to drink alcohol by giving mice a drug that blocks a specific response from the immune system in the brain. This research is one of the first of its kind to show a link between the brain's immunity and the motivation to drink alcohol at night. Read

9/11/17--ASU researcher Madeline Meier, who has been on the forefront of medical-marijuana health research, confirmed that Arizona State University wants to study individuals who consume cannabis legally as Arizona medical-marijuana patients. However, what is unclear is exactly what the study is trying to determine, beyond the effects of different "types" of cannabis. Read

8/24/17--Two new studies have been launched to determine how marijuana could possibly better treat pain. One study is from the federal government, which still lists marijuana as a Schedule I illegal drug, and the other is from the National Football League, which can still suspend players for marijuana use. A majority of Americans already think it should be legal for medicinal purposes, and 29 states already have legalized it, but federal law has kept the number of studies in this country limited. Read

8/25/17--Dale Quigley, deputy coordinator of the National Marijuana Initiative, or NMI, has asked Massachusetts health officials for data on the age, gender, and medical condition of the state’s approximately 40,000 registered medical marijuana patients. Quigley is a former police officer in Colorado with a long history of speaking out against legalization. Read

8/21/17--Researchers at the VA Portland Health Care System published two studies that reviewed previous analyses and evaluations of the effects of marijuana on treating chronic pain and PTSD. Cannabis advocates are criticizing the Department of Veterans Affairs for wasting time and resources on recently published research that produced inconclusive results on the effects of medical marijuana in treating pain and post-traumatic stress disorder. Read

8/21/17--According to a new study conducted by a Canadian researcher at the University of Victoria, “a compelling amount of evidence” indicates that marijuana could be used as an alternative to opioids, creating “significant positive impacts on public health and safety.” The study describes a “substitution effect” in states with medical marijuana, suggesting that people who want to quit using prescription opioids and other powerful pharmaceuticals have already started switching to cannabis. Read

8/22/17--Although recent studies from the Department of Veterans Affairs suggest that cannabis is ineffective in the treatment of PTSD and chronic pain, soldiers of the scientific community agree that this research is the same “worthless,” rehashed noise that the federal government has been trying to sell the general public for decades. Read

8/12/17--The National Institutes of Health (NIH) is funding the first-ever, long-term study to research the impacts of medical marijuana on opioid use. The NIH has awarded a five-year, $3.8 million grant to researchers at Albert Einstein College of Medicine and Montefiore Health System to study whether medical marijuana reduces opioid use among adults with chronic pain, including people with HIV. Read

8/7/17--New research suggests that an investigational neurological treatment derived from cannabis may alter the blood levels of commonly used antiepileptic drugs. Read

8/7/17--New research published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), suggests that an investigational neurological treatment derived from cannabis may alter the blood levels of commonly used antiepileptic drugs. Read